Glaucoma in both eyes was associated with visual-field decline
A review linked glaucoma affecting both eyes with visual-field worsening. Evidence for many other proposed predictors remained uncertain.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Having glaucoma in both eyes was associated with visual-field worsening, supported by moderate-certainty evidence. Associations involving optic-disc bleeding and glaucoma treatment had lower certainty. The abstract reports mixed or uncertain evidence for many other predictors. This abstract-based summary cannot provide a precise forecast for an individual patient.
Most included studies were judged at high risk of bias. That limits confidence in the review; the relative hazard does not describe an individual's probability of losing vision.
What researchers found
Adjusted hazard ratio for visual-field worsening
For both-eye versus one-eye glaucoma over at least 2 years, the rate of worsening at any given time was estimated at 1.77 times as high. The confidence interval spans 1.35 to 2.32 times, showing uncertainty. Evidence certainty was moderate.
How progression was measured
Most studies measured progression through worsening visual fields. Others combined these functional assessments with structural measurements, such as retinal nerve-fiber thickness, so the review considered several ways of identifying deterioration.
Other associations were less certain
Optic-disc bleeding was associated with progression, while glaucoma treatment was associated with less progression. Both findings had low-certainty evidence, leaving limited confidence in the strength of these relationships.
The original publication
Prognostic factors associated with progression of open-angle glaucoma in adults.
Piyasena MP, Daka Q, Qureshi R et al.
Cochrane Database Syst Rev · 2025
- PubMed ID
- 41370133
- Record checked
Linked publication notices
- UpdateOf
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.